Overall, baseline characteristics appear comparable; however, prostate cancer severity and cardiac history between patients receiving degarelix vs GnRH agonists differed (in the degarelix group, PSA levels were higher and more patients had cardiac disease at baseline). This evidence concerns the gene KLK3 and prostate carcinoma.